Sensex
82,248.61 profit arw -27.46 (-0.03%)
Nifty
25,496.55 profit arw 14.05 (0.06%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 25-Feb-2026
Corporate News
25-Feb-2026     12:05

Biocon receives USFDA approval for Liraglutide

Biocon has received approval from the U.S. FDA, for its complex formulation Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda').

Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity.

GLP-1 receptor agonists have emerged as one of the fastest growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

82,248.61 -27.46 (-0.03%)

Nifty

25,496.55 14.05 (0.06%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

26,381.03 -384.70(-1.44%)